Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals reported second-quarter revenues of $211.3 million, up 27.7% year on year and exceeding analysts' expectations by 2.8%, as the broader group of 9 branded pharmaceuticals stocks tracked reported a strong quarter with revenues beating consensus estimates by 6.6% as a group. The company said full-year operating income guidance exceeded analysts' expectations and full-year revenue guidance slightly topped them, prompting President and CEO Jack Khattar to cite the continued strength and sustained momentum of its growth products and continued execution on its commercial strategy. Despite the beat, Supernus shares are down 5.9% since reporting and currently trade at $41.99. Among peers, Bristol-Myers Squibb reported revenues of $12.97 billion, up 5.7% year on year and 12.9% above expectations, while Corcept Therapeutics posted revenues of $256.1 million, up 31.7% and 21.6% above estimates, the biggest beat and highest full-year guidance raise of the group. Zoetis delivered the weakest performance, with revenues of $2.47 billion, flat year on year and 1.5% below expectations, alongside a significant miss of full-year EPS guidance estimates.

Corcept Therapeutics reported second-quarter revenues of $256.1 million, up 31.7% year on year and beating analysts' expectations by 21.6%, making it the standout performer among eight branded pharmaceutical stocks tracked. The company also beat EPS estimates and raised full-year revenue guidance above expectations, with its stock up 28.1% since reporting to trade at $119.05. Bristol-Myers Squibb posted revenues of $12.97 billion, up 5.7% and 12.9% above estimates, while Eli Lilly delivered the fastest revenue growth at 47.7% to $22.97 billion, beating by 11.4%. Zoetis was the weakest, with flat revenues of $2.47 billion missing estimates by 1.5% and lowering full-year guidance. Supernus Pharmaceuticals reported $211.3 million in revenue, up 27.7% and 2.8% above estimates.

Several major acquisition agreements were announced this week. DoubleVerify agreed to be acquired by Nielsen in an all-cash transaction valued at approximately $2.15 billion, with shareholders receiving $13.60 per share. Advanced Micro Devices signed a definitive agreement to acquire Taalas, a developer of specialized AI inference silicon. Visa agreed to acquire BioCatch, a provider of behavioral-first fraud intelligence, for $2.4 billion from funds advised by Permira. Prologis reached an agreement to buy SEGRO plc for about $18.8 billion after securing a board recommendation. Bending Spoons is acquiring Airtable in an all-cash transaction valuing the workflow software company at an enterprise value of $1.285 billion, implying an equity value of about $2.25 billion. Curium announced a deal to acquire all outstanding shares of Lantheus Holdings for up to $114.50 per share in cash, including contingent value rights. Atkore entered into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8 billion. Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to merge in an all-stock merger of equals. Digital Brands Group shares surged after receiving a proposal from an existing shareholder to acquire all outstanding shares for $77.58 per share in cash. Gloo entered into a definitive agreement to acquire Cedarstone, a business services firm serving nonprofit organizations.

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on central nervous system disorders. The combined entity is expected to generate pro forma net revenue of $2.2 billion and will unite commercial portfolios spanning 11 medicines in neurology, addiction, and psychiatry. Supernus brings assets including ADHD drug Qelbree and Parkinson’s treatment Gocovri, while Indivior contributes opioid use disorder therapies such as Sublocade, which recorded $856 million in 2025 revenue. The merger is projected to deliver around $125 million in annual cost synergies and is anticipated to close in the fourth quarter of 2026, with Supernus CEO Jack Khattar leading the new company, which will trade on Nasdaq under the ticker SUPN.

Supernus Pharmaceuticals reported second-quarter 2026 revenue of $219.06 million, a 32.4% increase from a year ago and 6.84% above the Zacks Consensus Estimate of $205.04 million. Earnings per share came in at $0.54, matching the consensus estimate but down from $0.91 a year earlier. Net product sales totaled $165.7 million, exceeding the $158.76 million analyst forecast, with Qelbree contributing $89.2 million and GOCOVRI adding $37.6 million. Royalty, licensing and other revenues surged 141.4% year over year to $18 million, far surpassing the $2.5 million estimate, while collaboration revenue from ZURZUVAE reached $35.4 million. The stock has declined 7.1% over the past month, compared with a 0.2% gain for the S&P 500.

Supernus Pharmaceuticals surged 20.7% in premarket trading after agreeing to an all-stock merger of equals with Indivior Pharmaceuticals. Under the deal, Supernus shareholders will receive 1.5401 Indivior shares for each share held, while Indivior shareholders will receive a one billion dollar special cash dividend before closing. The combined company will retain the Supernus name and continue trading under the SUPN ticker. Other notable movers included GameStop, which slipped six percent after announcing a debt-for-equity swap that will exchange approximately 1.4 billion dollars of convertible debt for newly issued Class A common stock, and Ferguson, which climbed 7.1 percent ahead of its inclusion in the S&P 500 on August fifth.

Branded pharmaceutical stocks reported mixed first-quarter results, with the group beating revenue estimates by 3.6% on average. Eli Lilly led the pack with revenue of $19.8 billion, up 55.5% year-on-year and exceeding expectations by 13.7%, while Zoetis posted the weakest performance with revenue of $2.26 billion, up 2.9% but missing estimates by 2.1%. Organon revenue fell 3.5% to $1.46 billion, Supernus Pharmaceuticals grew 38.6% to $207.7 million, and Pfizer rose 5.4% to $14.45 billion. Since reporting, Eli Lilly shares have surged 41.1%, while Zoetis shares have dropped 35.8%.

Supernus Pharmaceuticals has expanded its partnership with MERGE, naming the agency its Agency of Record for the ADHD treatment QELBREE and its full digital ecosystem. The expanded agreement unifies Supernus' digital marketing and technology platforms, with MERGE leading omnichannel strategy and taking over website development and CRM operations. MERGE will continue to support Supernus' Parkinson's disease brands APOKYN, GOCOVRI, and ONAPGO, while using its Contextual Spectrum approach to deliver personalized digital experiences. The partnership builds on a seven-year relationship and will leverage MERGE's AI-first blueprint to enhance engagement across Supernus' CNS portfolio.